ClinicalTrials.gg

Program

Epoetin Alfa

Also written as “epoetin alfa”, “Epoetin alfa” and “Epoetin Hospira”.

Its studies are mostly in Anemia · Renal Insufficiency, Chronic · Kidney Failure, Chronic · Acquired Immunodeficiency Syndrome · Neoplasms, led by 16 companies.

Furthest: phase 4, since Sep 13, 2005117 company-led studies, 1 open or runningNext primary completion: Dec 2026 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Johnson & Johnson660 open or runningphase 4since Sep 13, 2005May 9, 2002none ahead
Ortho Biotech Products, L.P.100 open or runningphase 4since Apr 14, 2006Jul 19, 2005none ahead
Novartis70 open or runningphase 4since Feb 29, 2008Feb 29, 2008none ahead
Azidus Brasil60 open or runningphase 3since Sep 26, 2012Nov 3, 2011none ahead
Ortho Pharmaceuticals60 open or runningno phasesince Nov 2, 1999Nov 2, 1999none ahead
Pfizer60 open or runningphase 3since Nov 2, 2011Jul 23, 2010none ahead
Amgen30 open or runningphase 4since Oct 3, 2012Jun 30, 2005none ahead
Bio Sidus30 open or runningphase 4since Jun 13, 2011Jun 13, 2011none ahead
3SBio20 open or runningphase 4since Aug 10, 2015Aug 10, 2015none ahead
Ortho Biotech20 open or runningphase 4since Nov 17, 2006Nov 17, 2006none ahead
incepta-pharmaceuticals-ltd10 open or runningphase 3since May 24, 2025May 24, 2025none ahead
Merck10 open or runningphase 2since Jun 18, 2009Jun 18, 2009none ahead
nanogen-pharmaceutical-biotechnology-joint-stock-company11 open or runningphase 1since Mar 26, 2025Mar 26, 2025Dec 2026phase 1 · NCT06919861
r-w-johnson-pharmaceutical-research-institute10 open or runningno phasesince Nov 2, 1999Nov 2, 1999none ahead
sports-medicine-research-and-testing-laboratory10 open or runningearly phase 1since Jul 28, 2019Jul 28, 2019none ahead
Zydus Lifesciences10 open or runningphase 3since Dec 22, 2019Dec 22, 2019none ahead

Also a collaborator on its studies: hexal-ag, navitas-life-sciences-gmbh, blau-farmaceutica-s-a and ortho-biotech-clinical-affairs-l-l-c.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 43 studies since Mar 24, 2006.

  1. Jul 25, 20124 phase 1 studies in HealthyAzidus Brasil · NCT01685333, NCT01664221, NCT01664195 and 1 more
  2. Sep 21, 2012Phase 3 study in AnemiaNovartis · NCT01693029 · 435 enrolled · United States
  3. Sep 26, 2012Phase 3 study in Renal Insufficiency, ChronicAzidus Brasil · NCT01695759 · 92 enrolled · Brazil
  4. Oct 3, 2012Phase 4 study in AnemiaAmgen · NCT01737879 · 41 enrolled · United States
  5. Sep 11, 2014Phase 4 study in Renal Insufficiency, ChronicAmgen · NCT02253654 · 216 enrolled · United States, Puerto Rico
  6. Jul 20, 2015Phase 3 study in Renal Insufficiency, ChronicPfizer · NCT02504294 · 432 enrolled · United States, Puerto Rico
  7. Aug 10, 20153SBio's first study: phase 4 study in Renal AnaemiaNew to 3SBio3SBio · NCT02522975 · 16 enrolled · Thailand
  8. Oct 26, 2016Phase 3 study in Renal Anemia3SBio · NCT02947438 · 207 enrolled · Russian Federation, Thailand
  9. Nov 11, 2016Phase 1 study in AnemiaBio Sidus · NCT03822884 · 24 enrolled
  10. Jul 12, 2019Phase 3 study in AnemiaBio Sidus · NCT04036253 · 43 enrolled · Argentina, Paraguay
  11. Jul 28, 2019sports-medicine-research-and-testing-laboratory's first study: early phase 1 study in Healthy AthletesNew to sports-medicine-research-and-testing-laboratorysports-medicine-research-and-testing-laboratory · NCT04073849 · 24 enrolled · United States
  12. Dec 22, 2019Zydus Lifesciences's first study: phase 3 study in Chronic Kidney Disease Stage 5 on DialysisNew to Zydus LifesciencesZydus Lifesciences · NCT04215120 · 392 enrolled · India
  13. Mar 26, 2025nanogen-pharmaceutical-biotechnology-joint-stock-company's first study: phase 1 study in Pharmacokinetics and Pharmacodynamics in Healthy VolunteersNew to nanogen-pharmaceutical-biotechnology-joint-stock-companynanogen-pharmaceutical-biotechnology-joint-stock-company · NCT06919861 · 44 planned
  14. May 24, 2025incepta-pharmaceuticals-ltd's first study: phase 3 study in HealthyNew to incepta-pharmaceuticals-ltdincepta-pharmaceuticals-ltd · NCT07025681 · 56 enrolled · Bangladesh

Ahead

  1. Dec 2026Primary completion: phase 1 study in Pharmacokinetics and Pharmacodynamics in Healthy Volunteersnanogen-pharmaceutical-biotechnology-joint-stock-company · NCT06919861

TargetBeta

EPOR →read by rule
“Erythropoietin receptor agonist”ChEMBL 37, by rule

Studies

The newest 60 of 117 led by companies developing it. Each opens its study page. Every study on its drug page →

StudyPhaseStatusLed byPrimary completionSize
NCT07025681Healthy · Bangladesh3Completedincepta-pharmaceuticals-ltdSep 23, 202556
NCT06919861Pharmacokinetics and Pharmacodynamics in Healthy Volunteers1Not yet recruitingnanogen-pharmaceutical-biotechnology-joint-stock-companyDec 202644
NCT04215120Chronic Kidney Disease Stage 5 on Dialysis · India3CompletedZydus LifesciencesSep 2, 2021392
NCT04073849Healthy Athletes · United StatesEarly 1Completedsports-medicine-research-and-testing-laboratoryNov 15, 202024
NCT04036253Anemia · Argentina, Paraguay3CompletedBio SidusJun 15, 202143
NCT03822884Anemia1CompletedBio SidusSep 201624
NCT02947438Renal Anemia · Russian Federation, Thailand3Completed3SBioOct 9, 2021207
NCT02522975Renal Anaemia · Thailand4Terminated3SBioJun 201916
NCT02504294Renal Insufficiency, Chronic · United States, Puerto Rico3CompletedPfizerJul 2, 2016432
NCT02253654Renal Insufficiency, Chronic · United States, Puerto Rico4CompletedAmgenApr 27, 2016216
NCT01737879Anemia · United States4TerminatedAmgenMar 201341
NCT01695759Renal Insufficiency, Chronic · Brazil3TerminatedAzidus BrasilDec 201492
NCT01693029Anemia · United States3CompletedNovartisMay 2014435
NCT01685359Healthy · Brazil1CompletedAzidus BrasilOct 31, 201380
NCT01685333Healthy · Brazil1CompletedAzidus BrasilOct 31, 201328
NCT01664221Healthy · Brazil1UNKNOWNAzidus BrasilOct 201380
NCT01664195Healthy · Brazil1UNKNOWNAzidus BrasilOct 201328
NCT01628120Kidney Failure, Chronic · United States3CompletedPfizerFeb 13, 2015170
NCT01628107Kidney Failure, Chronic · United States, Puerto Rico3CompletedPfizerJan 2, 2015406
NCT01576341Renal Insufficiency, Chronic · Germany, Italy, Poland and more3CompletedNovartisOct 2014417
NCT03572647Renal Insufficiency, Chronic · Brazil1CompletedAzidus BrasilNov 201240
NCT01473420Kidney Failure, Chronic · United States3CompletedPfizerFeb 28, 2014320
NCT01473407Renal Insufficiency, Chronic · United States, Puerto Rico3CompletedPfizerFeb 11, 2014612
NCT01381809Myelodysplastic Syndromes · Bulgaria, France, Germany and more3CompletedJohnson & JohnsonJan 2015130
NCT01374373Anemia · Argentina4CompletedBio SidusNov 201430
NCT01394991Anemia4CompletedJohnson & JohnsonSep 2009504
NCT01170078Kidney Failure, Chronic · United States1CompletedPfizerJan 2011107
NCT00924781Anemia2TerminatedMerckApr 201039
NCT00869856Anemia · Bulgaria, France, Germany and more3WithdrawnNovartisAug 20090
NCT00711958Anemia · Germany, Romania3CompletedNovartisJul 2005114
NCT00701714Anemia · Austria, Bulgaria, Czechia and more3TerminatedNovartisJul 2009337
NCT00695396Myelodysplastic Syndromes3TerminatedJohnson & JohnsonJan 201025
NCT00666835Anemia · Austria, Germany3CompletedNovartisJan 2006478
NCT00641589Renal Insufficiency, Chronic1CompletedJohnson & Johnson40
NCT00632125Renal Insufficiency, Chronic · Austria, Bulgaria, France and more4CompletedNovartisMar 20101,695
NCT00524407Anemia4CompletedOrtho Biotech273
NCT00495378Neoplasms4TerminatedOrtho Biotech Products, L.P.25
NCT00495365Anemia4TerminatedOrtho Biotech Products, L.P.8
NCT00446602Myelodysplastic Syndromes2WithdrawnJohnson & Johnson0
NCT00446576Anemia3CompletedJohnson & Johnson176
NCT00440557Anemia · United States, Puerto Rico3CompletedJohnson & JohnsonFeb 2008375
NCT00440466Anemia · United States3CompletedJohnson & JohnsonMar 2009430
NCT00401869Anemia4CompletedOrtho Biotech289
NCT00388336Anemia2CompletedJohnson & Johnson57
NCT00386152Neoplasms · United States2TerminatedJohnson & JohnsonMar 2008235
NCT00364455Carcinoma3CompletedJohnson & Johnson56
NCT00364260Anemia3CompletedJohnson & Johnson172
NCT00350519Hemostasis, Surgical4TerminatedJohnson & JohnsonFeb 200837
NCT00350090Anemia3TerminatedOrtho Biotech Products, L.P.98
NCT00341055Anemia3CompletedJohnson & Johnson69
NCT00338468Anemia4TerminatedOrtho Biotech Products, L.P.13
NCT00338416Neoplasms2CompletedJohnson & Johnson115
NCT00338299Anemia2CompletedJohnson & Johnson51
NCT00338000Kidney Failure, Chronic4CompletedJohnson & Johnson292
NCT00337948Anemia2CompletedJohnson & Johnson129
NCT00337935Renal Insufficiency, Chronic2CompletedJohnson & JohnsonJul 2009157
NCT00317902Anemia4CompletedOrtho Biotech Products, L.P.292
NCT00315484Anemia4CompletedOrtho Biotech Products, L.P.358
NCT00312871Anemia4TerminatedJohnson & Johnson217
NCT00307814Anemia2CompletedOrtho Biotech Products, L.P.519

How it is read

Names in the registry

  • “epoetin alfa”, 47 entries
  • “Epoetin alfa”, 33 entries
  • “Epoetin Alfa”, 11 entries
  • “Epoetin Hospira”, 5 entries
  • “Erythropoietin alfa”, 4 entries

Codes read as this program: HX575.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.